{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T18:10:11Z","timestamp":1792087811468,"version":"4.4.0"},"reference-count":56,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Fc\u03b3Rs are key regulators of the immune response, capable of binding to the Fc portion of IgG Abs and manipulating the behavior of numerous cell types. Through a variety of receptors, isoforms, and cellular expression patterns, they are able to fine-tune and direct appropriate responses. Furthermore, they are key determinants of mAb immunotherapy, with mAb isotype and Fc\u03b3R interaction governing therapeutic efficacy. Critical to understanding the biology of this complex family of receptors are reagents that are robust and highly specific for each receptor. In this study, we describe the development and characterization of mAb panels specific for both mouse and human Fc\u03b3R for use in flow cytometry, immunofluorescence, and immunocytochemistry. We highlight key differences in expression between the two species and also patterns of expression that will likely impact on immunotherapeutic efficacy and translation of therapeutic agents from mouse to clinic.<\/jats:p>","DOI":"10.4049\/jimmunol.1402988","type":"journal-article","created":{"date-parts":[[2015,10,29]],"date-time":"2015-10-29T02:10:17Z","timestamp":1446084617000},"page":"5503-5516","source":"Crossref","is-referenced-by-count":45,"title":["Development and Characterization of Monoclonal Antibodies Specific for Mouse and Human Fc\u03b3 Receptors"],"prefix":"10.1093","volume":"195","author":[{"given":"Alison L","family":"Tutt","sequence":"first","affiliation":[{"name":"Antibody and Vaccine Group, Cancer Sciences Unit, University of Southampton Faculty of Medicine, Southampton General Hospital , Southampton, Hampshire SO16 6YD ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonya","family":"James","sequence":"additional","affiliation":[{"name":"Antibody and Vaccine Group, Cancer Sciences Unit, University of Southampton Faculty of Medicine, Southampton General Hospital , Southampton, Hampshire SO16 6YD ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phanie A","family":"Laversin","sequence":"additional","affiliation":[{"name":"Antibody and Vaccine Group, Cancer Sciences Unit, University of Southampton Faculty of Medicine, Southampton General Hospital , Southampton, Hampshire SO16 6YD ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas R W","family":"Tipton","sequence":"additional","affiliation":[{"name":"Antibody and Vaccine Group, Cancer Sciences Unit, University of Southampton Faculty of Medicine, Southampton General Hospital , Southampton, Hampshire SO16 6YD ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"Ashton-Key","sequence":"additional","affiliation":[{"name":"Antibody and Vaccine Group, Cancer Sciences Unit, University of Southampton Faculty of Medicine, Southampton General Hospital , Southampton, Hampshire SO16 6YD ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth R","family":"French","sequence":"additional","affiliation":[{"name":"Antibody and Vaccine Group, Cancer Sciences Unit, University of Southampton Faculty of Medicine, Southampton General Hospital , Southampton, Hampshire SO16 6YD ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khiyam","family":"Hussain","sequence":"additional","affiliation":[{"name":"Antibody and Vaccine Group, Cancer Sciences Unit, University of Southampton Faculty of Medicine, Southampton General Hospital , Southampton, Hampshire SO16 6YD ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew T","family":"Vaughan","sequence":"additional","affiliation":[{"name":"Antibody and Vaccine Group, Cancer Sciences Unit, University of Southampton Faculty of Medicine, Southampton General Hospital , Southampton, Hampshire SO16 6YD ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lang","family":"Dou","sequence":"additional","affiliation":[{"name":"Antibody and Vaccine Group, Cancer Sciences Unit, University of Southampton Faculty of Medicine, Southampton General Hospital , Southampton, Hampshire SO16 6YD ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Earley","sequence":"additional","affiliation":[{"name":"Antibody and Vaccine Group, Cancer Sciences Unit, University of Southampton Faculty of Medicine, Southampton General Hospital , Southampton, Hampshire SO16 6YD ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lekh N","family":"Dahal","sequence":"additional","affiliation":[{"name":"Antibody and Vaccine Group, Cancer Sciences Unit, University of Southampton Faculty of Medicine, Southampton General Hospital , Southampton, Hampshire SO16 6YD ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Lu","sequence":"additional","affiliation":[{"name":"Antibody and Vaccine Group, Cancer Sciences Unit, University of Southampton Faculty of Medicine, Southampton General Hospital , Southampton, Hampshire SO16 6YD ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Dunscombe","sequence":"additional","affiliation":[{"name":"Antibody and Vaccine Group, Cancer Sciences Unit, University of Southampton Faculty of Medicine, Southampton General Hospital , Southampton, Hampshire SO16 6YD ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H T Claude","family":"Chan","sequence":"additional","affiliation":[{"name":"Antibody and Vaccine Group, Cancer Sciences Unit, University of Southampton Faculty of Medicine, Southampton General Hospital , Southampton, Hampshire SO16 6YD ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine A","family":"Penfold","sequence":"additional","affiliation":[{"name":"Antibody and Vaccine Group, Cancer Sciences Unit, University of Southampton Faculty of Medicine, Southampton General Hospital , Southampton, Hampshire SO16 6YD ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinny H","family":"Kim","sequence":"additional","affiliation":[{"name":"Antibody and Vaccine Group, Cancer Sciences Unit, University of Southampton Faculty of Medicine, Southampton General Hospital , Southampton, Hampshire SO16 6YD ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth A","family":"Potter","sequence":"additional","affiliation":[{"name":"Antibody and Vaccine Group, Cancer Sciences Unit, University of Southampton Faculty of Medicine, Southampton General Hospital , Southampton, Hampshire SO16 6YD ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C Ian","family":"Mockridge","sequence":"additional","affiliation":[{"name":"Antibody and Vaccine Group, Cancer Sciences Unit, University of Southampton Faculty of Medicine, Southampton General Hospital , Southampton, Hampshire SO16 6YD ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Roghanian","sequence":"additional","affiliation":[{"name":"Antibody and Vaccine Group, Cancer Sciences Unit, University of Southampton Faculty of Medicine, Southampton General Hospital , Southampton, Hampshire SO16 6YD ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J","family":"Oldham","sequence":"additional","affiliation":[{"name":"Antibody and Vaccine Group, Cancer Sciences Unit, University of Southampton Faculty of Medicine, Southampton General Hospital , Southampton, Hampshire SO16 6YD ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerry L","family":"Cox","sequence":"additional","affiliation":[{"name":"Antibody and Vaccine Group, Cancer Sciences Unit, University of Southampton Faculty of Medicine, Southampton General Hospital , Southampton, Hampshire SO16 6YD ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean H","family":"Lim","sequence":"additional","affiliation":[{"name":"Antibody and Vaccine Group, Cancer Sciences Unit, University of Southampton Faculty of Medicine, Southampton General Hospital , Southampton, Hampshire SO16 6YD ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid","family":"Teige","sequence":"additional","affiliation":[{"name":"BioInvent International , 22362 Lund ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bjorn","family":"Frend\u00e9us","sequence":"additional","affiliation":[{"name":"BioInvent International , 22362 Lund ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin J","family":"Glennie","sequence":"additional","affiliation":[{"name":"Antibody and Vaccine Group, Cancer Sciences Unit, University of Southampton Faculty of Medicine, Southampton General Hospital , Southampton, Hampshire SO16 6YD ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen A","family":"Beers","sequence":"additional","affiliation":[{"name":"Antibody and Vaccine Group, Cancer Sciences Unit, University of Southampton Faculty of Medicine, Southampton General Hospital , Southampton, Hampshire SO16 6YD ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2077-089X","authenticated-orcid":false,"given":"Mark S","family":"Cragg","sequence":"additional","affiliation":[{"name":"Antibody and Vaccine Group, Cancer Sciences Unit, University of Southampton Faculty of Medicine, Southampton General Hospital , Southampton, Hampshire SO16 6YD ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2015,12,1]]},"reference":[{"key":"2025030704260838000_r1","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1146\/annurev.immunol.19.1.275","article-title":"IgG Fc receptors","volume":"19","author":"Ravetch","year":"2001","journal-title":"Annu. Rev. Immunol."},{"key":"2025030704260838000_r2","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1038\/nature05329","article-title":"Global variation in copy number in the human genome","volume":"444","author":"Redon","year":"2006","journal-title":"Nature"},{"key":"2025030704260838000_r3","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1038\/ng.237","article-title":"Integrated genotype calling and association analysis of SNPs, common copy number polymorphisms and rare CNVs","volume":"40","author":"Korn","year":"2008","journal-title":"Nat. Genet."},{"key":"2025030704260838000_r4","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/BF00218905","article-title":"Human high-affinity Fc gamma RI (CD64) gene mapped to chromosome 1q21.2-q21.3 by fluorescence in situ hybridization","volume":"93","author":"Takai","year":"1994","journal-title":"Hum. Genet."},{"key":"2025030704260838000_r5","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1159\/000134330","article-title":"The three genes of the human FCGR1 gene family encoding Fc gamma RI flank the centromere of chromosome 1 at 1p12 and 1q21","volume":"73","author":"Maresco","year":"1996","journal-title":"Cytogenet. Cell Genet."},{"key":"2025030704260838000_r6","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/nri2206","article-title":"Fcgamma receptors as regulators of immune responses","volume":"8","author":"Nimmerjahn","year":"2008","journal-title":"Nat. Rev. Immunol."},{"key":"2025030704260838000_r7","first-page":"175","article-title":"Expression of IgG Fc receptor antigens in placenta and on endothelial cells in humans. An immunohistochemical study","volume":"138","author":"Sedmak","year":"1991","journal-title":"Am. J. Pathol."},{"key":"2025030704260838000_r8","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.4049\/jimmunol.156.4.1549","article-title":"Dermal microvascular endothelial cells express CD32 receptors in vivo and in vitro","volume":"156","author":"Gr\u00f6ger","year":"1996","journal-title":"J. Immunol."},{"key":"2025030704260838000_r9","doi-asserted-by":"crossref","first-page":"3882","DOI":"10.4049\/jimmunol.166.6.3882","article-title":"The Fc receptor for IgG expressed in the villus endothelium of human placenta is Fc gamma RIIb2","volume":"166","author":"Lyden","year":"2001","journal-title":"J. Immunol."},{"key":"2025030704260838000_r10","doi-asserted-by":"crossref","first-page":"3823","DOI":"10.1016\/j.molimm.2007.06.151","article-title":"Mechanisms of killing by anti-CD20 monoclonal antibodies","volume":"44","author":"Glennie","year":"2007","journal-title":"Mol. Immunol."},{"key":"2025030704260838000_r11","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s00281-006-0052-1","article-title":"Activating and inhibitory FcgammaRs in autoimmune disorders","volume":"28","author":"Nimmerjahn","year":"2006","journal-title":"Springer Semin. Immunopathol."},{"key":"2025030704260838000_r12","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.4049\/jimmunol.1101135","article-title":"Interaction with Fc\u03b3RIIB is critical for the agonistic activity of anti-CD40 monoclonal antibody","volume":"187","author":"White","year":"2011","journal-title":"J. Immunol."},{"key":"2025030704260838000_r13","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.4049\/jimmunol.1303204","article-title":"Fc\u03b3 receptor dependency of agonistic CD40 antibody in lymphoma therapy can be overcome through antibody multimerization","volume":"193","author":"White","year":"2014","journal-title":"J. Immunol."},{"key":"2025030704260838000_r14","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1126\/science.1206954","article-title":"Inhibitory Fc\u03b3 receptor engagement drives adjuvant and anti-tumor activities of agonistic CD40 antibodies","volume":"333","author":"Li","year":"2011","journal-title":"Science"},{"key":"2025030704260838000_r15","first-page":"355","article-title":"Fc\u03b3RIIB as a key determinant of agonistic antibody efficacy","volume":"382","author":"White","year":"2014","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"2025030704260838000_r16","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1158\/2326-6066.CIR-13-0013","article-title":"Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells","volume":"1","author":"Selby","year":"2013","journal-title":"Cancer Immunol. Res."},{"key":"2025030704260838000_r17","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1084\/jem.20130579","article-title":"Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma","volume":"210","author":"Simpson","year":"2013","journal-title":"J. Exp. Med."},{"key":"2025030704260838000_r18","doi-asserted-by":"crossref","first-page":"4174","DOI":"10.4049\/jimmunol.1300409","article-title":"Agonist anti-human CD27 monoclonal antibody induces T cell activation and tumor immunity in human CD27-transgenic mice","volume":"191","author":"He","year":"2013","journal-title":"J. Immunol."},{"key":"2025030704260838000_r19","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1084\/jem.20130573","article-title":"Activating Fc \u03b3 receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies","volume":"210","author":"Bulliard","year":"2013","journal-title":"J. Exp. Med."},{"key":"2025030704260838000_r20","doi-asserted-by":"crossref","first-page":"7346","DOI":"10.1016\/S0021-9258(18)53181-1","article-title":"The human low affinity immunoglobulin G Fc receptor IIC gene is a result of an unequal crossover event","volume":"268","author":"Warmerdam","year":"1993","journal-title":"J. Biol. Chem."},{"key":"2025030704260838000_r21","doi-asserted-by":"crossref","first-page":"4170","DOI":"10.1182\/blood-2008-04-149161","article-title":"Type II (tositumomab) anti-CD20 monoclonal antibody out performs type I (rituximab-like) reagents in B-cell depletion regardless of complement activation","volume":"112","author":"Beers","year":"2008","journal-title":"Blood"},{"key":"2025030704260838000_r22","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1053\/j.seminhematol.2010.01.001","article-title":"CD20 as a target for therapeutic type I and II monoclonal antibodies","volume":"47","author":"Beers","year":"2010","journal-title":"Semin. Hematol."},{"key":"2025030704260838000_r23","doi-asserted-by":"crossref","first-page":"e88703","DOI":"10.1371\/journal.pone.0088703","article-title":"Fc\u03b3 receptor-mediated inflammation inhibits axon regeneration","volume":"9","author":"Zhang","year":"2014","journal-title":"PLoS One"},{"key":"2025030704260838000_r24","doi-asserted-by":"crossref","first-page":"5424","DOI":"10.1074\/jbc.M114.593806","article-title":"Activatory and inhibitory Fc\u03b3 receptors augment rituximab-mediated internalization of CD20 independent of signaling via the cytoplasmic domain","volume":"290","author":"Vaughan","year":"2015","journal-title":"J. Biol. Chem."},{"key":"2025030704260838000_r25","doi-asserted-by":"crossref","first-page":"5275","DOI":"10.1074\/jbc.272.8.5275","article-title":"Affinity and kinetics of the interaction between soluble trimeric OX40 ligand, a member of the tumor necrosis factor superfamily, and its receptor OX40 on activated T cells","volume":"272","author":"Al-Shamkhani","year":"1997","journal-title":"J. Biol. Chem."},{"key":"2025030704260838000_r26","doi-asserted-by":"crossref","first-page":"981","DOI":"10.4049\/jimmunol.138.3.981","article-title":"Analysis of the interaction of antibodies with immunoglobulin idiotypes on neoplastic B lymphocytes: implications for immunotherapy","volume":"138","author":"Elliott","year":"1987","journal-title":"J. Immunol."},{"key":"2025030704260838000_r27","doi-asserted-by":"crossref","first-page":"2595","DOI":"10.4049\/jimmunol.143.8.2595","article-title":"Studies of aglycosylated chimeric mouse-human IgG. Role of carbohydrate in the structure and effector functions mediated by the human IgG constant region","volume":"143","author":"Tao","year":"1989","journal-title":"J. Immunol."},{"key":"2025030704260838000_r28","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.ccell.2015.03.005","article-title":"Antagonistic human Fc\u03b3RIIB (CD32B) antibodies have anti-tumor activity and overcome resistance to antibody therapy in vivo","volume":"27","author":"Roghanian","year":"2015","journal-title":"Cancer Cell"},{"key":"2025030704260838000_r29","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1038\/78458","article-title":"Recombining germline-derived CDR sequences for creating diverse single-framework antibody libraries","volume":"18","author":"S\u00f6derlind","year":"2000","journal-title":"Nat. Biotechnol."},{"key":"2025030704260838000_r30","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1002\/eji.201142302","article-title":"Development and characterisation of monoclonal antibodies specific for the murine inhibitory Fc\u03b3RIIB (CD32B)","volume":"42","author":"Williams","year":"2012","journal-title":"Eur. J. Immunol."},{"key":"2025030704260838000_r31","doi-asserted-by":"crossref","first-page":"3176","DOI":"10.4049\/jimmunol.161.6.3176","article-title":"Monoclonal antibody therapy of B cell lymphoma: signaling activity on tumor cells appears more important than recruitment of effectors","volume":"161","author":"Tutt","year":"1998","journal-title":"J. Immunol."},{"key":"2025030704260838000_r32","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1084\/jem.150.3.580","article-title":"Characterization of a monoclonal antibody directed against mouse macrophage and lymphocyte Fc receptors","volume":"150","author":"Unkeless","year":"1979","journal-title":"J. Exp. Med."},{"key":"2025030704260838000_r33","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.coi.2007.01.005","article-title":"Antibodies, Fc receptors and cancer","volume":"19","author":"Nimmerjahn","year":"2007","journal-title":"Curr. Opin. Immunol."},{"key":"2025030704260838000_r34","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.jim.2005.08.004","article-title":"Flow cytometric assay for determination of FcgammaRIIIA-158 V\/F polymorphism","volume":"306","author":"B\u00f6ttcher","year":"2005","journal-title":"J. Immunol. Methods"},{"key":"2025030704260838000_r35","doi-asserted-by":"crossref","first-page":"3146","DOI":"10.1182\/blood.V97.10.3146","article-title":"Human natural killer cells: a unique innate immunoregulatory role for the CD56(bright) subset","volume":"97","author":"Cooper","year":"2001","journal-title":"Blood"},{"key":"2025030704260838000_r36","doi-asserted-by":"crossref","first-page":"3183","DOI":"10.4049\/jimmunol.143.10.3183","article-title":"Comparative studies of human FcRIII-positive and negative natural killer cells","volume":"143","author":"Nagler","year":"1989","journal-title":"J. Immunol."},{"key":"2025030704260838000_r37","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1182\/blood-2007-03-079913","article-title":"Copy number variation of the activating FCGR2C gene predisposes to idiopathic thrombocytopenic purpura","volume":"111","author":"Breunis","year":"2008","journal-title":"Blood"},{"key":"2025030704260838000_r38","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1007\/BF00177829","article-title":"Variation in human FCGR2C gene copy number","volume":"40","author":"Reilly","year":"1994","journal-title":"Immunogenetics"},{"key":"2025030704260838000_r39","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.ajhg.2012.11.013","article-title":"Genomic pathology of SLE-associated copy-number variation at the FCGR2C\/FCGR3B\/FCGR2B locus","volume":"92","author":"Mueller","year":"2013","journal-title":"Am. J. Hum. Genet."},{"key":"2025030704260838000_r40","doi-asserted-by":"crossref","first-page":"3879","DOI":"10.1172\/JCI75539","article-title":"FCGR2C polymorphisms associate with HIV-1 vaccine protection in RV144 trial","volume":"124","author":"Li","year":"2014","journal-title":"J. Clin. Invest."},{"key":"2025030704260838000_r41","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1189\/jlb.1212623","article-title":"Neutrophils in local and systemic antibody-dependent inflammatory and anaphylactic reactions","volume":"94","author":"J\u00f6nsson","year":"2013","journal-title":"J. Leukoc. Biol."},{"key":"2025030704260838000_r42","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1182\/blood-2011-01-330357","article-title":"Fc gamma receptor IIb on target B cells promotes rituximab internalization and reduces clinical efficacy","volume":"118","author":"Lim","year":"2011","journal-title":"Blood"},{"key":"2025030704260838000_r43","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1182\/blood-2013-04-490821","article-title":"Inhibitory Fc\u03b3RIIb (CD32b) becomes activated by therapeutic mAb in both cis and trans and drives internalization according to antibody specificity","volume":"123","author":"Vaughan","year":"2014","journal-title":"Blood"},{"key":"2025030704260838000_r44","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/bjh.13071","article-title":"Expression of the inhibitory Fc gamma receptor IIB (FCGR2B, CD32B) on follicular lymphoma cells lowers the response rate to rituximab monotherapy (SAKK 35\/98)","volume":"168","author":"Lee","year":"2015","journal-title":"Br. J. Haematol."},{"key":"2025030704260838000_r45","doi-asserted-by":"crossref","first-page":"4130","DOI":"10.4049\/jimmunol.1301430","article-title":"Immunotherapy targeting inhibitory Fc\u03b3 receptor IIB (CD32b) in the mouse is limited by monoclonal antibody consumption and receptor internalization","volume":"191","author":"Williams","year":"2013","journal-title":"J. Immunol."},{"key":"2025030704260838000_r46","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/978-1-4614-7654-2_3","article-title":"Overcoming resistance to therapeutic antibodies by targeting Fc Receptors","volume":"2","author":"Williams","year":"2013","journal-title":"Resistance Immunother. Antibodies Cancer"},{"key":"2025030704260838000_r47","doi-asserted-by":"crossref","first-page":"2832","DOI":"10.1002\/ijc.23870","article-title":"Selective expression of inhibitory Fcgamma receptor by metastatic melanoma impairs tumor susceptibility to IgG-dependent cellular response","volume":"123","author":"Cassard","year":"2008","journal-title":"Int. J. Cancer"},{"key":"2025030704260838000_r48","doi-asserted-by":"crossref","first-page":"657406","DOI":"10.1155\/2010\/657406","article-title":"Metastatic melanomas express inhibitory low affinity fc gamma receptor and escape humoral immunity","volume":"2010","author":"Cohen-Solal","year":"2010","journal-title":"Dermatol. Res. Pract."},{"key":"2025030704260838000_r49","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1097\/01.shk.0000142249.08135.e9","article-title":"Innate immune response in Th1- and Th2-dominant mouse strains","volume":"22","author":"Watanabe","year":"2004","journal-title":"Shock"},{"key":"2025030704260838000_r50","doi-asserted-by":"crossref","first-page":"19501","DOI":"10.1073\/pnas.1319502110","article-title":"Antitumor activities of agonistic anti-TNFR antibodies require differential FcgammaRIIB coengagement in vivo","volume":"110","author":"Li","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2025030704260838000_r51","doi-asserted-by":"crossref","first-page":"3736","DOI":"10.1002\/1521-4141(200212)32:12<3736::AID-IMMU3736>3.0.CO;2-I","article-title":"FcgammaRIIb expression on human germinal center B lymphocytes","volume":"32","author":"Macardle","year":"2002","journal-title":"Eur. J. Immunol."},{"key":"2025030704260838000_r52","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1056\/NEJMoa063842","article-title":"Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412","volume":"355","author":"Suntharalingam","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"2025030704260838000_r53","doi-asserted-by":"crossref","first-page":"6772","DOI":"10.1182\/blood-2010-12-319780","article-title":"Preculture of PBMCs at high cell density increases sensitivity of T-cell responses, revealing cytokine release by CD28 superagonist TGN1412","volume":"118","author":"R\u00f6mer","year":"2011","journal-title":"Blood"},{"key":"2025030704260838000_r54","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.4049\/jimmunol.1302461","article-title":"Cell contact-dependent priming and Fc interaction with CD32+ immune cells contribute to the TGN1412-triggered cytokine response","volume":"192","author":"Bartholomaeus","year":"2014","journal-title":"J. Immunol."},{"key":"2025030704260838000_r55","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1182\/blood-2014-08-593061","article-title":"Upregulation of Fc\u03b3RIIb on monocytes is necessary to promote the superagonist activity of TGN1412","volume":"125","author":"Hussain","year":"2015","journal-title":"Blood"},{"key":"2025030704260838000_r56","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1136\/jcp.2007.047720","article-title":"Technical pitfalls potentially affecting diagnoses in immunohistochemistry","volume":"61","author":"Bussolati","year":"2008","journal-title":"J. Clin. Pathol."}],"container-title":["The Journal of Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jimmunol\/article-pdf\/195\/11\/5503\/62248819\/1402988.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jimmunol\/article-pdf\/195\/11\/5503\/62248819\/1402988.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T05:27:12Z","timestamp":1741325232000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jimmunol\/article\/195\/11\/5503\/7973356"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12,1]]},"references-count":56,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2015,12,1]]}},"URL":"https:\/\/doi.org\/10.4049\/jimmunol.1402988","relation":{},"ISSN":["0022-1767","1550-6606"],"issn-type":[{"value":"0022-1767","type":"print"},{"value":"1550-6606","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2015,12]]},"published":{"date-parts":[[2015,12,1]]}}}